Immunotherapy dominated the American Society of Clinical Oncology 2018 annual meeting. PD-1/L1 inhibitors were among those taking center stage–find out which ones hold the most promise for NSCLC. Gain insights into why Jounce’s ICOS antibody JTX-2011 proved to be such a disappointment–and why this affects Celgene investors.
Author: Jessica Merrill
Published: 17 May 2018
Number of pages:4
As seems to have become the norm, immunotherapy dominated the American Society of Clinical Oncology 2018 annual meeting with PD-1/L1 inhibitors and chimeric antigen receptor T-cell (CAR-T) therapies taking center stage. Learn how the findings on Roche’s PD-L1 inhibitor Tecentriq and Merck’s Keytruda could make a difference in the treatment of non-small cell lung cancer, and discover what other companies reported on their cancer (NSCLC), therapies. Gain insights into why Jounce’s ICOS antibody JTX-2011 proved to be such a disappointment–and why that upset Celgene investors. Learn about the research into CAR-T therapies, including Celgene’s JCAR017 and bluebird bio’s bb2121.
This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.